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Abstract 26 
Contaminated pork is a major source of human salmonellosis and the serovar most frequently 27 
isolated from pigs is Salmonella Typhimurium. Vaccination could contribute greatly to 28 
controlling Salmonella infections in pigs. However, pigs vaccinated with the current vaccines 29 
cannot be discriminated from infected pigs with the LPS-based serological tests used in 30 
European Salmonella serosurveillance programmes. We therefore examined which LPS 31 
encoding genes of Salmonella Typhimurium can be deleted to allow differentiation of 32 
infected and vaccinated pigs (DIVA), without affecting the vaccine strain‟s protective 33 
capacity. For this purpose, deletion mutants in Salmonella strain 112910a, used as vaccine 34 
strain, were constructed in the LPS encoding genes: ∆rfbA, ∆rfaL, ∆rfaJ, ∆rfaI, ∆rfaG and 35 
∆rfaF. Primary inoculation of BALB/c mice with the parent strain, ∆rfaL, ∆rfbA or ∆rfaJ 36 
strain but not the ∆rfaG, ∆rfaF or ∆rfaI strain protected significantly against subsequent 37 
infection with the virulent Salmonella Typhimurium strain NCTC12023. Immunization of 38 
piglets with the ∆rfaJ or ∆rfaL mutants resulted in the induction of a serological response 39 
lacking detectable antibodies against LPS. This allowed a clear differentiation between sera 40 
from pigs immunized with the ∆rfaJ or ∆rfaL strains and sera from pigs infected with their 41 
isogenic wild type strain. In conclusion, applying deletions in the rfaJ or the rfaL gene in 42 
Salmonella Typhimurium strain 112910a allows differentiation of infected and vaccinated 43 
pigs in an LPS based ELISA without reducing the strain‟s protective capacities in mice.  44 
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1. Introduction 51 
Salmonellosis is one of the most important bacterial zoonotic diseases in humans and 52 
Salmonella infections are often linked with the consumption of contaminated pork 
[1] [2]
. The 53 
serovar most frequently isolated from pigs is Salmonella enterica subspecies enterica serovar 54 
Typhimurium (Salmonella Typhimurium), which is also the most prevalent serovar in humans 55 
[3]
. In order to reduce human Salmonella Typhimurium infections, minimization of the 56 
Salmonella intake into the food chain is very important and efforts to reduce transmission of 57 
Salmonellae by food should be implemented on a global scale 
[2]
. A combined approach using 58 
hygienic measures, the use of feed additives and different protection measures, such as 59 
vaccination, has been proposed to reduce the contamination on farms 
[3] [4] [5]
. Vaccination has 60 
already proven to be efficient in laying hens, reducing faecal shedding and internal egg 61 
contamination of Salmonella, resulting in reduction of the number of human salmonellosis 62 
cases 
[6] [7]
. Currently, one licensed Salmonella Typhimurium live vaccine for pigs is 63 
commercially available in Europe 
[8]
 and has shown to reduce both shedding and colonization 64 
of host tissues 
[9]
 and to induce a substantial Salmonella antibody response seven days after 65 
the second immunization 
[10]
. These antibodies are, however, not distinguishable from those 66 
induced after a wild type Salmonella Typhimurium infection. An isogenic mutant of the 67 
Salmonella vaccine strain was developed, which lacks the ompD gene. This allowed 68 
differentiation of infected and vaccinated animals, using an OmpD based enzyme-linked 69 
immunosorbent assay (ELISA) 
[9]
. Unfortunately, this DIVA-vaccine (Differentiation of 70 
Infected and Vaccinated Animals) is not broadly applicable, despite its ability to reduce 71 
colonization 
[9]
, because European Salmonella serosurveillance programmes are mostly based 72 
on the detection of antibodies against the lipopolysaccharides (LPS) of Salmonella 
[11]
. It was 73 
therefore the aim of this study to develop and characterize LPS mutations that might be used 74 
as DIVA markers with application in the currently used monitoring programmes in the EU. 75 
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Since a marker should not affect the vaccine strain‟s protective capacity, we first compared 76 
the protective capacity of LPS mutants and their parent strain in a standardized mouse virulent 77 
assay. Secondly, the LPS deletion mutants were tested for their capability to elicit a DIVA 78 
antibody response in pigs.  79 
2. Materials and methods 80 
All in vivo experiments were approved by the ethical committee of the Faculty of Veterinary 81 
Medicine, Ghent University (EC 2009/124, EC 2009/131, EC 2010/080 and EC 2010/108). 82 
2.1 Bacterial strains 83 
Salmonella Typhimurium strain 112910a, phage type 120/ad, isolated from a pig stool sample 84 
and characterized previously 
[4]
, was used as the wild type background to construct several 85 
isogenic LPS knock-out mutants: ∆rfbA, ∆rfaL, ∆rfaJ, ∆rfaI, ∆rfaG, ∆rfaF. These strains 86 
were used for immunization of mice and pigs. The bacterial strains and primers used in this 87 
study are shown in table 1A/B. The knock-out mutants were constructed as described before 88 
[12]
. Briefly, the genes of interest were first substituted by a PCR adjusted antibiotic resistance 89 
cassette (kanamycin) using the helper plasmid pKD46. This plasmid encodes the phage λ Red 90 
system, which promotes recombination between the native gene and the PCR adjusted 91 
antibiotic resistance cassette. Recombinant clones were selected by plating on Luria-Bertani 92 
agar (LB; Sigma Aldrich Chemie Gmbh, Steinheim, Germany) containing 100 µg/ml 93 
kanamycin. The substitution was confirmed by PCR. In the last step, the antibiotic resistance 94 
cassettes were eliminated using the helper plasmid pcp20. The targeted genes were 95 
completely deleted from the start codon through the stop codon, as confirmed by sequencing. 96 
Salmonella challenge strains comprised, spontaneous mutants resistant to 20 µg/ml nalidixic 97 
acid (Nal
20
) in a NCTC12023 Salmonella Typhimurium strain highly virulent in BALB/c 98 
mice, in Salmonella Enteritidis strain SE147, in Salmonella Heidelberg strain 704Sa06 and in 99 
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Salmonella Typhimurium strain 112910a. All bacteria were routinely grown in LB broth or on 100 
brilliant green agar (BGA) at 37 °C, unless stated otherwise.  101 
2.2 Characterization of the LPS knock-out mutants of Salmonella Typhimurium 102 
Validation of the LPS phenotype occurred by SDS-polyacrylamide gel electrophoresis and 103 
fluorescent staining. For this purpose LPS was isolated from Salmonella Typhimurium strain 104 
112910a and its isogenic knock-out mutants using a commercially available LPS extraction 105 
kit (Intron biotechnology, Gyeonggi-do, Korea). The obtained LPS was quantified using a 106 
ToxinSensor
TM
 Chromogenic LAL Endotoxin Assay Kit (GenScript, Piscataway, USA) and 107 
was separated by standard SDS-polyacrylamide gel electrophoresis. LPS was stained using a 108 
Molecular probes Pro-Q Emerald LPS Gel stain kit (Invitrogen, Oregon, USA), creating a 109 
bright green-fluorescent signal, which was visualised with a 300 nm UV-transilluminator. To 110 
verify whether LPS mutant strains (∆rfbA, ∆rfaL, ∆rfaJ, ∆rfaI, ∆rfaG, ∆rfaF) were still 111 
expressing O-antigens on their surface, an in vitro agglutination test (PRO-LAB O4 and O12 112 
antisera, diagnostics, Austin, Texas) was performed, according to the manufacturer‟s 113 
instructions. The smooth phenotype was also tested by checking sensitivity of Salmonella 114 
Typhimurium and its isogenic knock-out mutants to bacteriophage P22 as described 115 
elsewhere 
[12]
. As a measure of in vitro virulence of the wild type strain and its isogenic 116 
mutants, invasiveness of all strains was assessed in porcine epithelial cells (IPEC-J2) using a 117 
gentamicin protection assay as described previously 
[13]
. 118 
2.3 ELISA procedures 119 
A commercially available enzyme-linked immunosorbent assay (ELISA) (HerdChek 120 
Salmonella; IDEXX Laboratories, Schiphol-Rijk, Noord-Holland, The Netherlands) for the 121 
detection of porcine antibodies against the LPS of Salmonella was used as a reference 122 
according to the manufacturer‟s instructions. Coating antigens in this ELISA include LPS of 123 
serogroups B, C1 and D (O-antigens 1, 4, 5, 6, 7 and 12) 
[14]
. Besides, an in-house Salmonella 124 
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Typhimurium strain 112910a whole cell ELISA, to detect porcine anti Salmonella 125 
Typhimurium antibodies, was prepared as follows. Salmonella Typhimurium strain 112910a 126 
was cultured overnight at 37 °C in 500 ml LB broth. Inactivation was achieved by adding 127 
0.18% (v/v) formalin overnight at 37 °C. The bacteria were centrifuged three times (5000 X g 128 
for 30 min at room temperature) and the resulting pellet was resuspended in a volume of 250 129 
ml Phosphate Buffered Saline (PBS) with 0.18% formalin and incubated overnight at 37 °C. 130 
The inactivated culture was centrifuged again (5000 X g for 10 min at 5 °C) and the pellet 131 
was resuspended in a final volume of 250 ml coating buffer (1.08 g Na2CO3.10H2O, 0.968 g 132 
NaHCO3, 0.25 l aqua ad iniectabilia 100 % w/v).  F96 maxisorp Nunc-immuno plates (Nunc; 133 
Denmark) were coated with 140 µl formalin-inactivated Salmonella strains diluted in coating 134 
buffer to an optical density of 660 nm, measured using a spectrophotometer (Ultraspec III 
®
), 135 
incubated for 24 h at 4 °C and washed three times with 100 µl wash buffer (0.6 g NaH2PO4. 136 
2H2O, 5.6 g NaH2PO4. 12H2O, 0.5 ml Tween 20 (Merck, Germany), 12.5 g NaCl). Plates 137 
were stored at 4 °C until used. Before starting the assay, the plates were washed with 100 µl 138 
destillated water (AD) + 1% milk powder to prevent non-specific binding. A 1/2000 dilution 139 
of sera (100 µl) was added to the wells. The cut-off optical density was calculated as the mean 140 
obtained from the sera from a bacteriologically and serologically Salmonella free pig (the 141 
negative control, determined using the HerdChek ELISA) plus two times the standard 142 
deviation. All measurements were performed in triplicate.  143 
2.4 Protective capacity of LPS mutant strains against Salmonella serovars 144 
The protective capacity of the LPS deletion mutants was compared to that of the wild type 145 
strain using a mouse model. Five-week-old specified pathogen-free (SPF) BALB/c mice (Bio 146 
services, Janvier, France) were housed in filter-topped cages at 25 °C under natural day-night 147 
rhythm with ad libitum acces to feed and water and enriched with mouse houses and play 148 
tunnels. Bacterial inocula used for oral protection assays were prepared as follows. Strains 149 
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were grown overnight on a shaker at 37 °C in 100 ml LB broth. The bacteria were washed 150 
twice in PBS at 3500 X g for 15 min at room temperature and adjusted in PBS to the 151 
appropriate concentration of 2 x 10
7
 colony forming units per ml (CFU/ml). The number of 152 
viable bacteria was determined by plating tenfold dilutions on BGA.   153 
 154 
In a first experiment, we tested whether the LPS mutants affect the protective capacity of 155 
Salmonella Typhimurium strain 112910a against a subsequent challenge with a highly 156 
virulent strain. For that purpose seven groups of ten mice were inoculated first via the 157 
orogastric route with 2 x 10
7
 CFU/ml of one of the LPS
 
mutant strains (either ∆rfbA, ∆rfaL, 158 
∆rfaJ, ∆rfaI, ∆rfaG or ∆rfaF) or with the wild type Salmonella Typhimurium strain 112910a. 159 
A control group of ten mice was sham-inoculated with sterile PBS. Four weeks after primary 160 
inoculation, all mice were challenged with a total of 10
8 
CFU/ml of the virulent Salmonella 161 
Typhimurium strain NCTC12023Nal
20 
by the orogastric route.  162 
 163 
In a second experiment, we tested whether truncation of the LPS chain in the ∆rfaJ strain 164 
promotes cross-immunity against other Salmonella serovars. Sixty mice were orally 165 
inoculated first with 2 x 10
7
 CFU/ml of either the ∆rfaJ strain (n = 20) or Salmonella 166 
Typhimurium strain 112910a (n = 20). A control group of 20 mice was sham-inoculated with 167 
sterile PBS (n = 20). Sixteen days after primary inoculation, ten mice of each group were 168 
challenged with a total of 10
8 
CFU/ml of either Salmonella Heidelberg strain 704Sa06 Nal
20
 169 
(n = 10) or Salmonella Enteritidis strain SE147 Nal
20
 (n = 10).   170 
 171 
In both in vivo experiments, mice were euthanized nine days post challenge. Tissue samples 172 
(spleen, liver and caecum) were examined quantitatively for the presence of the respective 173 
Salmonella strain. Samples were weighed and 10% (w/v) suspensions were made in buffered 174 
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peptone water (BPW; Oxoid, Basingstoke, UK) after which the material was homogenized 175 
with a stomacher. The homogenized samples were examined for the presence of Salmonella 176 
by plating 10-fold dilutions on BGA supplemented with nalidixic acid (BGA
NAL
). If negative 177 
at direct plating, the samples were pre-enriched overnight in BPW at 37 °C, enriched 178 
overnight at 37 °C in tetrathionate broth and then plated on BGA
NAL
. Samples that were 179 
negative after direct plating but positive after enrichment were presumed to contain 60 CFU 180 
per gram tissue (detection limit for direct plating). Samples that remained negative after 181 
enrichment were presumed to contain 0 CFU per gram tissue.  182 
2.5 Immunization of piglets  183 
In this study, we examined whether it was possible to discriminate between the serological 184 
response induced after immunization of pigs with the wild type and its isogenic ∆rfaL and 185 
∆rfaJ strains. For this purpose, we immunized pigs with adjuvanted bacterins of either the 186 
wild type strain, the ∆rfaL strain or the ∆rfaJ strain to maximize antibody production [15]. 187 
Fourteen, 6-week-old, bacteriologically and serologically Salmonella negative piglets 188 
(commercial closed line based on Landrace) were housed together at 25 °C under natural day-189 
night rhythm with ad libitum access to feed and water.  190 
For preparation of antigen suspensions for immunization of pigs, strains were cultured for 9 191 
hours at 37 °C in 400 ml LB broth and were adjusted to 5 x 10
8 
CFU/ml. Inactivation was 192 
achieved by adding 0.18% (v/v) formalin (VWR international, Fontenay sous bois, France) 193 
overnight at 37 °C. The formalin-inactivated Salmonella strains were washed twice (5000 X g 194 
for 30 min at room temperature) and the resulting pellet was resuspended in 11 ml PBS with 195 
0.18% formalin and incubated overnight. Thereafter, this suspension was mixed with 11 ml 196 
marcol oil (Esso Belgium nv, Antwerp, Belgium) containing 3.4% sterilized Tween 80 197 
(Sigma Aldrich Chemie Gmbh, Steinheim, Germany) and 6.4% mannide monooleate (Sigma 198 
Aldrich Chemie Gmbh, Steinheim, Germany). To check sterility, all suspensions were 199 
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cultured on Columbia agar plates containing 5% sheep blood (COL; Oxoid, Wesel, Germany) 200 
and incubated aerobically and anaerobically overnight at 37 °C.  201 
Piglets were randomly allocated to three vaccinated groups (n = 4) and one sham-vaccinated 202 
control group (n = 2). One and three weeks after their arrival, pigs were intramuscularly 203 
immunized with one of the formalin-inactivated Salmonella strains (either: Salmonella 204 
Typhimurium strain 112910a, ∆rfaJ or ∆rfaL) with Freund‟s incomplete adjuvant to elicit an 205 
optimal humoral (antibody-mediated/Th2) response 
[15]
. The control group was injected with 1 206 
ml of sterile PBS. Four weeks after the second immunization, the pigs were humanely 207 
euthanized and blood samples were taken from the vena jugularis externa, using a Venoject 208 
system (Terumo; Roma, Italia). All sera samples were examined for the presence of anti 209 
Salmonella Typhimurium antibodies using the Herdchek ELISA and the in-house Salmonella 210 
Typhimurium strain 112910a whole cell ELISA, prepared as described previously.  211 
2.6 Experimental infection of piglets with Salmonella Typhimurium 212 
To obtain sera from Salmonella Typhimurium infected piglets, an experimental infection was 213 
performed with 4 week-old bacteriologically and serologically Salmonella negative piglets 214 
(commercial closed line based on Landrace). Piglets were randomly allocated in one 215 
experimental group (n = 3) and one negative control group (n = 3) and both groups were 216 
housed in separate isolation units at 25°C under natural day-night rhythm with ad libitum 217 
access to feed and water. One week after their arrival at the facility, three experimental 218 
animals were orally inoculated with approximately 2 x 10
7
 CFU/ml of a stationary phase 219 
culture of Salmonella Typhimurium strain 112910aNal
20
 in 2 ml Hank‟s buffered salt solution 220 
(HBSS; Gibco Life Technologies, Paisley, Scotland); the negative control group (n = 3) was 221 
sham-inoculated with 2 ml HBSS. The clinical condition of the pigs was monitored daily. Six 222 
weeks after oral inoculation, pigs were humanely euthanized and blood samples were taken 223 
from the vena jugularis externa, using a Venoject system (Terumo; Roma, Italia). All sera 224 
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samples were examined for the presence of anti Salmonella Typhimurium antibodies using 225 
the Herdchek ELISA and the in-house Salmonella Typhimurium strain 112910a whole cell 226 
ELISA, prepared as described previously.  227 
2.7 Statistical analysis   228 
In all experiments, statistical analysis was performed using a one-way ANOVA test (in case 229 
of homogeneity of variances), with posthoc Bonferroni corrections or a nonparametric Mann-230 
Whitney-U-test (in case of non-homogeneity of variances), using the SPSS Statistics 17.0 231 
software (SPSS Inc., Chicago, USA). ELISA results were analysed by a one-way ANOVA 232 
and Bonferroni corrections were applied. A P-value of < 0.05 was considered significant.  233 
3. Results 234 
3.1 Characterization of the LPS knock-out mutants of Salmonella Typhimurium 235 
 A systematic truncation of the LPS chain occurred as a result of defects in genes coding for 236 
glycosyl or phosphoryl transferases (or epimerases) and is shown in figure 1. LPS patterns 237 
obtained by standard SDS-polyacrylamide gel electrophoresis of Salmonella Typhimurium 238 
strain 112910a, the O-antigen mutant (∆rfbA), the outer core mutants (∆rfaL, ∆rfaJ, ∆rfaI) 239 
and the inner core mutants (∆rfaG, ∆rfaF) are presented in figure 2 and show a visible loss of 240 
O-antigens for core mutants (∆rfaL, ∆rfaJ, ∆rfaI , rfaG, ∆rfaF) compared to Salmonella 241 
Typhimurium strain 112910a. Loss of the rfbA gene resulted in the presence of a complete 242 
core without covalently bound O-antigen (“semirough” LPS), because the rfb locus is 243 
responsible for the biosynthesis of O-antigen 
[16]
. The complete lack of O-antigens in core 244 
mutants was also confirmed by resistance to bacteriophage P22 and appearance of the “rough” 245 
phenotype. Salmonella Typhimurium strain 112910a showed the “wild-type” LPS structure 246 
and is denoted as “smooth” LPS [16].  247 
A slide agglutination test was used to verify expression of O-antigens on the surface of 248 
Salmonella Typhimurium 112910a and its isogenic knock-out mutants. While Salmonella 249 
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Typhimurium strain 112910a showed a distinct agglutination within 60 seconds, little 250 
granular clumping was seen with the rfbA mutant strain. No agglutination was observed with 251 
∆rfaL, ∆rfaJ, ∆rfaI, ∆rfaG and ∆rfaF strains, which confirmed a total loss of O4 and O12 252 
antigens.  253 
Further, invasion of Salmonella Typhimurium strain 112910a and its isogenic knock-out 254 
strains was compared in an IPEC-J2 cell strain, using a gentamicin protection assay. The 255 
∆rfbA, ∆rfaG and ∆rfaF strains showed a statistically significant decrease (P < 0.05) in 256 
invasion when compared to the 112910a strain, while the ∆rfaL, ∆rfaJ and ∆rfaI strains were 257 
not impaired in invasion. Results are summarized in figure 3.  258 
3.2 Deletion of rfaI, rfaG, rfaF genes but not rfaL and rfaJ severely affects the protective 259 
capacity of Salmonella Typhimurium strain 112910a in BALB/c mice 260 
Oral immunization of mice with Salmonella Typhimurium strain 112910a, ∆rfbA, ∆rfaL or 261 
∆rfaJ strains induced a significant (P < 0.05) protection against subsequent challenge with 262 
NCTC12023Nal
20
 in both spleen and liver compared to non immunized control animals. 263 
Bacterial counts (wild type, ∆rfbA, ∆rfaL and ∆rfaJ) in caecum samples showed a non 264 
significant (P > 0.05) reduction of the numbers of Salmonella Typhimurium compared with 265 
with control animals. Deletion of rfaI, rfaG and rfaF genes but not rfbA, rfaL and rfaJ genes 266 
thus significantly (P < 0.05) reduced protection against challenge with Salmonella 267 
Typhimurium strain NCTC12023Nal
20
. None of the animals immunized with ∆rfbA, ∆rfaG or 268 
∆rfaF died as a result of vaccination, whereas eight mice vaccinated with either strain 269 
112910a (n = 3), ∆rfaL (n = 2), ∆rfaJ (n = 2) or ∆rfaI (n = 1) died as a consequence of 270 
vaccination. After challenge, > 60% of the unvaccinated animals or mice vaccinated with 271 
either ∆rfaG or ∆rfaF died opposed to < 40% of mice vaccinated with wild type, ∆rfaL or 272 
∆rfaJ. Results are illustrated in figure 4.  273 
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3.3 Immunization with the ∆rfaJ strain does not confer enhanced cross-protection 274 
against subsequent challenge with serovars Heidelberg and Enteritidis in BALB/c mice    275 
In this experiment we determined to which extent the ∆rfaJ strain and Salmonella 276 
Typhimurium strain 112910a were able to confer cross-protection against Salmonella 277 
Heidelberg or Salmonella Enteritidis. Both strains were equally able to induce a significant (P 278 
< 0.05) reduction of Salmonella Heidelberg in the spleen compared to control animals. In 279 
liver and caecum both strains induced a noticeable, but non significant (P > 0.05) reduction of 280 
Salmonella Heidelberg compared to control animals.  281 
Recovery of Salmonella Enteritidis was not significantly different (P < 0.05) in spleen, liver 282 
and caecum between animals immunized with Salmonella Typhimurium strain 112910a and 283 
mice immunized with ∆rfaJ. Results are shown in figure 5.   284 
3.4 Immunological responses in pigs      285 
IDEXX ELISA No significant seroconversion (P > 0.05) was noticed in pigs immunized with 286 
inactivated ∆rfaJ or ∆rfaL strains and in control animals (non immunized and non infected 287 
animals). Conversely, marked seroconversion occurred in animals immunized or orally 288 
infected with the inactivated Salmonella Typhimurium strain 112910a. Statistical analysis 289 
showed a significant difference (P < 0.05) between the antibody response against Salmonella 290 
Typhimurium LPS in pigs infected with Salmonella Typhimurium 112910a and control 291 
animals. Results are shown in figure 6. Results also illustrate a clear differentiation between 292 
sera from piglets immunized with the ∆rfaJ strain or ∆rfaL strain and sera of pigs infected 293 
with their isogenic wild type strain. 294 
Whole-cell ELISA Significant anti-Salmonella-antibody titers were detected in the serum of 295 
all immunized and infected animals. No significant distinction (P > 0.05) regarding 296 
Salmonella-specific antibody responses could be made between animals that were immunized 297 
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with the inactivated 112910a strain and those immunized with the inactivated ∆rfaJ and ∆rfaL 298 
strains. Results are shown in figure 6.  299 
4. Discussion 300 
Marker vaccines are a recent advance in vaccinology enabling distinction between an animal 301 
that is seropositive to a particular infectious agent because it has been vaccinated, and one that 302 
is seropositive because it has been infected with virulent field organisms 
[17]
. Because current 303 
Salmonella serosurveillance programmes are generally based on detection of antibodies 304 
against LPS antigens, we selected six LPS genes that might be suitable markers to develop a 305 
LPS based DIVA-vaccine. Deletion of LPS genes, however, has some consequences: LPS 306 
represent the main surface antigens of Gram-negative bacteria (O-antigens) and harbour 307 
binding-sites for antibodies 
[18]
. Therefore, LPS are important in the recognition and the 308 
elimination of bacteria by the host‟s immune system [19]. Truncation of LPS may lead to over-309 
attenuated strains that are not able to fully colonize their host and therefore no longer elicit a 310 
sufficient protective immune response 
[20]
. Possibly smooth LPS are indispensable for the 311 
early steps of the infection process 
[21]
 and contribute to invasiveness 
[22]
. Data on LPS and 312 
invasion are often unclear and sometimes contradictory 
[22]
. Our results on invasiveness of 313 
Salmonella Typhimurium strain 112910a and its isogenic LPS mutants, illustrate that the 314 
∆rfbA, ∆rfaG and ∆rfaF strains were less able to invade IPEC-J2 cells, which might indicate 315 
that these strain are less able to colonize their host and therefore are no longer able to elicit a 316 
protective immune response. In a mouse in vivo experiment we showed that the rfaG and rfaF 317 
mutant strains were indeed not able to protect BALB/c mice against a subsequent infection 318 
with Salmonella Typhimurium NCT12023Nal
20
 and that the ∆rfaI strain was only able to 319 
significantly reduce bacterial counts in the spleen of mice. Conversely, ∆rfbA, ∆rfaL and 320 
∆rfaJ strains, with less truncated LPS, were able to successfully protect BALB/c mice against 321 
a Salmonella Typhimurium infection and their protective capacity was not impaired compared 322 
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to their isogenic wild type strain. These results strongly suggest that a confined truncation of 323 
LPS is essential to maintain protection against challenge with the virulent strain Salmonella 324 
Typhimurium NCTC12023Nal
20
 in mice. 325 
Cross-protection against other enterobacterial pathogens induced by „rough‟ mutants is 326 
sometimes explained by better accessibility of less immune-potent molecules, such as lipid A 327 
and core antigens 
[21] [23] [24]
. Hence, truncation of LPS might confer enhanced cross protection 328 
to other serovars. Therefore, we used the ∆rfaJ strain to conduct a cross-protection study. The 329 
finding that smooth strains are less capable of inducing a cross-protection against other 330 
Salmonella serovars could not be confirmed in this study. The wild type and the ∆rfaJ 331 
deficient strains were equally able to provoke cross-protection against Salmonella Heidelberg, 332 
whereas only the wild type strain was able to protect against a challenge with Salmonella 333 
Enteritidis.  334 
The ultimate goal of this study was to verify whether LPS mutant strains were able to elicit a 335 
DIVA humoral immune response in pigs. Our results illustrate that both the ∆rfaL and the 336 
∆rfaJ strain gave no seroconversion when using a LPS based ELISA, while a clear-cut 337 
seroconversion was observed when using an in-house Salmonella Typhimurium 338 
strain112910a whole cell ELISA. Besides, immunization of piglets with the ∆rfaJ or ∆rfaL 339 
mutants resulted in the induction of a serological response allowing clear differentiation 340 
between sera from piglets immunized with the ∆rfaJ or ∆rfaL strains and sera of pigs infected 341 
with their isogenic wild type strain when using a LPS based ELISA. 342 
In conclusion, we proved that immunization with Salmonella Typhimurium strain 112910a 343 
and its isogenic mutant strains: ∆rfaL and ∆rfaJ, is equally able to provoke protection against 344 
a virulent Salmonella Typhimurium strain. In addition, deletion of the rfaL or the rfaJ genes 345 
can be used as DIVA markers in current Salmonella serosurveillance programmes based on 346 
the detection of antibodies against LPS of Salmonella. 347 
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Figures 353 
Strain Genotype and O-antigens Product of the deleted gene Source or reference 
WT Salmonella Typhimurium 112910a  
(O: 1, 4, 12) 
no deletions                  [4] 
NCTC12023Nal20 Salmonella Typhimurium  NCTC 12023 
Nal20  (O: 1. 4, 12) 
no deletions [25] 
∆rfaL Salmonella Typhimurium 112910a  ∆rfaL Salmonella Typhimurium O-
antigen ligase 
This study 
∆rfaJ Salmonella Typhimurium 112910a  ∆rfaJ LPS 1,2-glucosyltransferase This study 
∆rfaI Salmonella Typhimurium 112910a  ∆rfaI LPS 1,3-galactosyltransferase This study 
∆rfaG Salmonella Typhimurium 112910a  ∆rfaG LPS core biosynthesis protein This study 
∆rfaF Salmonella Typhimurium 112910a  ∆rfaF LPS heptosyltransferase II This study 
Salmonella Enteritidis Salmonella Enteritidis Nal20 
(O: 1, 9, 12) 
no deletions This study 
Salmonella Heidelberg Salmonella Heidelberg Nal20 
(O: 1, 4, 5, 12) 
no deletions This study 
∆rfbA Salmonella Typhimurium 112910a  ∆rfbA glucose-1-phosphate 
thymidylyltransferase 
This study 
WT Nal20 Salmonella Typhimurium 112910a Nal20 
(O: 1, 4, 12) 
no deletions [4] 
Table 1A: Strains used in this study 354 
 355 
 356 
 357 
 358 
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Primers Sequences 
rfbA forward 5‟- TAATAAATTTAAATGCCCATCAGGGCATTTTCTATGAATGAGAAATGGAATGTGTAGGCTGGAGCTGCTTC - 3‟ 
rfbA reverse 5‟- GGCTCTAAGATCAAGACATCTGGTATTGCTGTTTTAATCACAATCACCATATGAATATCCTCCTTAG -3‟ 
 
rfaL forward 5‟-  CATTAAAGAGACTCTGTCTCATCCCAAACCTATTGTGGAGAAAAGTGTGTAGGCTGGAGCTGCTTC - 3‟ 
rfaL reverse 5‟ - TTGAGTCCTGATGATGGAAAACGCGCTGATACCGTCATATGAATATCCTCCTTAG -  3‟ 
 
rfaJ forward 5‟ - ATAGCCTACTTTAAACGTAAACTTCTTGAATAAAACCCATAGGTGATGTATGTGTAGGCTGGAGCTGCTTC - 3‟ 
rfaJ reverse 5‟ -  AGTTTTTAATCTTTTTTTCAATAATCATAATGGAGATTTAGGGAGGGGAACATATGAATATCCTCCTTAG -3‟ 
rfaI forward 5„ -  TTTAAAAATTTTAATAATGCAATATTCTCGAAATTACAAAAGTGATCACTTGTGTAGGCTGGAGCTGCTTC  - 3‟ 
rfaI reverse 5‟ - TTCAGCTATTTCTATCTCAGGAAATGAATCCATTACATCACCTATGGGTTCATATGAATATCCTCCTTAG - 3‟ 
 
rfaG forward 5‟- GAAAAAATGCTGCCGCATGAGGCACGCACCATAGATTTGGACAGCCTGCTTGTGTAGGCTGGAGCTGCTTC - 3‟ 
rfaG reverse 5‟ - CCTCAAAAGCATCTTTACCGCGCCATAGTGTGGTTAACGGCGCTTTCAGCCATATGAATATCCTCCTTAG -3‟ 
rfaF forward 5‟ - GCCGAAGGCGTCACGGAGTATATGGCCTGGCTGAACCGCGACGCGTAAGTTGTGTAGGCTGGAGCTGCTTC - 3‟ 
rfaF reverse 5‟ – GGTATGTAATACGTCGCCCATCGATGATGTTTTAACGATCAAAACCCGCACATATGAATATCCTCCTTAG – 3‟ 
Table 1B: Primers used in this study 359 
 360 
Figure 1: Schematic representation of the structure of lipopolysaccharide (LPS). Truncation of the LPS chain as 361 
a consequence of ∆rfbA, ∆rfaL, ∆rfaJ, ∆rfaI, ∆rfaG and ∆rfaF deletions is shown (G: glucose, L: galactose, H: 362 
heptose, K: 2-keto 3-deoxy-octulosonate (KDO), N: N-acetylglucosamine).  363 
 364 
 365 
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    366 
Figure 2: SDS-polyacrylamide gel electrophoresis patterns of LPS of Salmonella Typhimurium 112910a (lane 1) 367 
and ∆rfbA (lane 2), ∆rfaL (lane 3), ∆rfaJ (lane 4), ∆rfaI (lane 5), ∆rfaG (lane 6) and ∆rfaF (lane 7) mutants is 368 
shown. Apart from Salmonella Typhimurium strain 112910a (lane 1) all strains show a classical „rough‟ type 369 
ladder pattern. Staining occurred with fluorescent staining and a ten-fold dilution of 25µg/ml LPS of each strain 370 
was loaded.   371 
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 372 
Figure 3: The invasiveness of Salmonella Typhimurium and its isogenic knock-out mutants in IPEC-J2 cells. 373 
The log values of the number of gentamicin protected bacteria are shown. The results represent the means of 374 
three independent experiments conducted in triplicate and standard deviations are given. An asterisk refers to a 375 
significantly lower invasion compared to the wild type strain (P < 0.05).  376 
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 377 
Figure 4: Recovery of Salmonella bacteria from various organs of mice immunized with either Salmonella 378 
Typhimurium, one of its isogenic LPS mutants or non immunized control animals and subsequently challenged 379 
with Salmonella Typhimurium strain NCTC12023Nal
20
. The log10 value of the ratio of CFU per gram sample 380 
and standard deviations are given. An asterisk refers to a significant difference with the control group (P < 0.05). 381 
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Figure 5A: Recovery of Salmonella Heidelberg bacteria from various organs of BALB/c mice immunized with 383 
Salmonella Typhimurium, one of its isogenic LPS mutants or uninfected animals subsequently challenged with 384 
Salmonella Heidelberg. The log10 average value of the number of CFU per gram sample is given with its 385 
standard deviation. An asterisk refers to a significant difference with the control group (P < 0.05). 386 
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 387 
Figure 5B: Recovery of Salmonella Enteritidis bacteria from various organs of BALB/c mice immunized with 388 
Salmonella Typhimurium, one of its isogenic LPS mutants or uninfected animals subsequently challenged with 389 
Salmonella Enteritidis. The log10 average value of the number of CFU per gram sample is given with its standard 390 
deviation. An asterisk refers to a significant difference with the control group (P < 0.05).  391 
 392 
Figure 6: Serological results of pigs immunized with ∆rfaL, ∆rfaJ or Salmonella Typhimurium strain 112910a, 393 
control pigs (animals that were not immunized and not infected) and pigs infected with Salmonella 394 
Typhimurium strain 112910a Nal
20
. Values are represented as a percentage compared to the wild type 395 
immunized group.  396 
 397 
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